EGFR and central nervous system cancer: Our results revealed that GS-A patients displayed the most favorable prognosis, which were characterized by a high mutation rate of genes including IDH1, ATRX and EGFR. Previously published reports indicated that IDH, ATRX and EGFR mutation status significantly influenced the prognosis of glioma patients (39).